Antigen-Specific Killing
Evaluate T cell recognition and tumor cell elimination using standardized cell-based killing models.
T Cell Killing Models
BACK TO THE LAB | Up to 25% OFF Selected Products for T Cell-Mediated Killing Research
Accelerate T cell-mediated tumor killing research with ready-to-use tumor cell models and immune cell systems designed for immunotherapy, CAR-T, and TCR-T studies.
Explore Promotion Products →
T Cell Killing Research
Evaluate T cell-mediated tumor killing using cell-based models that support target recognition, T cell activation, cytotoxicity, and quantitative assessment.
CAR-T & TCR-T Evaluation
Assess immune-mediated tumor killing and therapeutic activity using CAR-T, TCR-T, and related approaches.
Tumor–Immune Cell Co-Culture
Model tumor–immune cell interactions using reproducible co-culture systems for cytotoxicity studies.
Quantitative Cytotoxicity
Quantify tumor cell killing using luciferase-based reporter models and functional assay readouts.
How T Cell Killing Is Evaluated
T cell-mediated tumor killing involves a sequence of recognition, activation, cytotoxic execution, and quantitative assessment. AcceGen provides complementary cell models to support key stages of this workflow.
01 Recognition & Activation
TCR/MHC or CAR/TAA interactions initiate T cell recognition, activation, and downstream signaling.
02 Cytotoxic Execution
Activated T cells eliminate target cells through cytotoxic granule release and death receptor pathways.
03 Killing Quantification
Reporter-expressing tumor cells enable quantitative assessment of tumor cell killing following co-culture.
Featured Products
UP TO 25% OFF Selected Cell Lines
Explore selected cell lines for T cell-mediated killing, CAR-T, and immunotherapy research.
| CAT.# | Product / Cell Line | Cell Origin | Key Features | Recommended Applications | Availability | Lead Time |
|---|---|---|---|---|---|---|
| ABC-TC0924 | Raji | Human Burkitt lymphoma | High CD19 expression | Target cells for CD19 CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-TC0487 | K562 | Human chronic myelogenous leukemia | MHC I/II-deficient; highly sensitive to immune cell-mediated cytotoxicity | T-cell cytotoxicity assays; CAR-T target cells after antigen transduction | In Stock | 1–3 weeks |
| ABC-TC252S | NALM-6 | Human B-cell acute lymphoblastic leukemia | High CD19 expression | Target cells for CD19 CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-TC0988 | RPMI-8226 | Human multiple myeloma | BCMA-positive | Target cells for BCMA CAR-T cytotoxicity assays | In Stock | 3–5 weeks |
| ABC-TC0032 | A549 | Human non-small cell lung carcinoma | Adherent cell line suitable for solid tumor CAR-T assays | Target cells for solid tumor CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-TC621S | MC38 | Murine colorectal carcinoma | Commonly used syngeneic mouse tumor model | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 1–3 weeks |
| ABC-TC0062 | B16-F10 | Murine melanoma | Commonly used syngeneic mouse tumor model | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 1–3 weeks |
| ABC-TC0197 | CT-26 | Murine colorectal carcinoma | Commonly used syngeneic mouse tumor model | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 1–3 weeks |
| ABC-TC0014 | 4T1 | Murine mammary carcinoma | Commonly used syngeneic mouse tumor model | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 1–3 weeks |
| ABC-RC206H | Raji-Luc | Human Burkitt lymphoma | Constitutive luciferase reporter cell line | Target cells for CD19 CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-RC187H | K562-Luc | Human chronic myelogenous leukemia | Constitutive luciferase reporter cell line | T-cell cytotoxicity assays; CAR-T target cells after antigen transduction | In Stock | 2–3 weeks |
| ABC-RC665H | NALM-6-Luc | Human B-cell acute lymphoblastic leukemia | Constitutive luciferase reporter cell line | Target cells for CD19 CAR-T cytotoxicity assays | In Stock | In stock |
| ABC-RC209H | RPMI-8226-Luc | Human multiple myeloma | Constitutive luciferase reporter cell line | Target cells for BCMA CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-RC130D | A549-Luc | Human non-small cell lung carcinoma | Constitutive luciferase reporter cell line | Target cells for solid tumor CAR-T cytotoxicity assays | In Stock | 2–3 weeks |
| ABC-RC149H | SK-OV-3-Luc | Human ovarian carcinoma | Constitutive luciferase reporter cell line | Target cells for HER2 CAR-T cytotoxicity assays | In Stock | 1–3 weeks |
| ABC-RC193H | MC38-Luc | Murine colorectal carcinoma | Constitutive luciferase reporter cell line | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | In stock |
| ABC-RC289H | B16-F10-Luc | Murine melanoma | Constitutive luciferase reporter cell line | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 2–3 weeks |
| ABC-RC587H | CT-26-Luc | Murine colorectal carcinoma | Constitutive luciferase reporter cell line | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | 2–3 weeks |
| ABC-RC286H | 4T1-Luc | Murine mammary carcinoma | Constitutive luciferase reporter cell line | Mouse CAR-T evaluation and in vivo tumor model studies | In Stock | In stock |
| ABC-TC3726 | Human PBMC | Healthy donors or patients | Mixed immune cell population | Source cells for T-cell isolation and functional assays | Made to Order | 4 weeks |
| ABC-TC3994 | Human CD3+ T Cells | Isolated from PBMCs | Purified T cells | CAR-T generation and functional validation | Made to Order | 4 weeks |
| ABC-TC3993 | Human CD4+ T Cells | Isolated from PBMCs | T helper cells | T-cell functional validation assays | Made to Order | 4 weeks |
| ABC-TC4005 | Human CD8+ T Cells | Isolated from PBMCs | Cytotoxic T cells | Cytotoxicity assays | Made to Order | 4 weeks |
| ABC-TC3113 | Human Primary NK Cells | Isolated from PBMCs | Natural killer cells | NK-cell cytotoxicity and ADCC assays | Made to Order | 4 weeks |
| ABC-HP029X | Mouse PBMC | C57BL/6 and other mouse strains | Suitable for syngeneic mouse models | Mouse CAR-T evaluation | Made to Order | 4 weeks |
| ABC-TC088G | Mouse CD3+ T Cells | Isolated from mouse PBMCs | Mouse T cells | Mouse CAR-T evaluation | Made to Order | 4 weeks |
| ABC-TC4002 | Human Treg Cells | Isolated from PBMCs | Regulatory T cells for immunosuppression studies | T-cell suppression assays | Made to Order | 4 weeks |
| ABC-RC101F | NFAT-Luc Reporter Jurkat Cell Line | Jurkat T-cell background | NFAT pathway luciferase reporter | Co-culture reporter assays for antigen-dependent T-cell activation | In Stock | 2–4 weeks |
| ABC-RC187Y | NF-kB Reporter Jurkat Cell Line | Jurkat T-cell background | NF-kB pathway reporter | T-cell activation and inflammatory signaling assays | In Stock | 2–4 weeks |
| ABC-RC068F | IL2-Promoter Reporter Jurkat Cell Line | Jurkat T-cell background | IL-2 promoter-driven reporter | T-cell functional validation; complementary reporter model to NFAT-Luc | In Stock | 2–4 weeks |
| ABC-RC091F | TNFRSF9 (4-1BB) Reporter Jurkat Cell Line | Jurkat T-cell background | 4-1BB co-stimulatory signaling reporter | Evaluation of co-stimulatory signaling in CAR-T activation models | In Stock | 2–4 weeks |
| ABC-RC075F | Human CD64 (Luc) Reporter Cell Line | Reporter cell background | CD64/Fc receptor-mediated luciferase reporter | ADCP activity assays and antibody Fc effector function evaluation | In Stock | 2–4 weeks |
